SMS Pharmaceuticals reported FY26 standalone net profit of ₹87.61 crore, up 28% YoY, with revenue of ₹886.87 crore.
Board recommended a final dividend of ₹0.40 per share (40%) for FY26, subject to shareholder approval.
Company shifted its registered office within Hyderabad and reappointed internal/cost auditors for FY27.
50 lakh warrants converted to equity shares during FY26, increasing paid-up capital to ₹9.36 crore.